Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging in HNSCC
NCT07741643Phase 1Recruiting
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Oct 2026
- Primary completion
- Jul 2031
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of panitumumab and [18F]NOTA-ABY030 in head and neck squamous cell carcinoma (HNSCC), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Adverse Events at 30 days. Started Oct 2026; status: recruiting.
02
Drugs
panitumumab[18F]NOTA-ABY030
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07741643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07741643.